Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA_1c value

References

• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes (2008);57:3169-76
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother (2009);7:324-42
   PubMed Web of Science ®Google Scholar
• Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc (2003);51:S265-80
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care (2011);34:1749-53
   PubMed Web of Science ®Google Scholar
• Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes (2011);4:251
   PubMedGoogle Scholar
• Pollack MF, Purayidathil FW, Bolge SC, et al. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract (2010);87:204-10
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ (2010);340:b4909
   PubMed Web of Science ®Google Scholar
• Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care (2011);34:1164-70
   PubMed Web of Science ®Google Scholar
• Brito-Sanfiel M, Diago-Cabezudo J, Calderon A. Economic impact of hypoglycemia on healthcare in Spain. Expert Rev Pharmacoecon Outcomes Res (2010);10:649-60
   PubMed Web of Science ®Google Scholar
• Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia (2010);53:1552-61
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ (2005);6:197-202
   PubMedGoogle Scholar
• Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health (2006);9:193-8
   PubMed Web of Science ®Google Scholar
• Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, (1999) to (2006). Am J Med (2009);122:443-53
   PubMed Web of Science ®Google Scholar
• Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract (2007);77:126-33
   PubMed Web of Science ®Google Scholar
• Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications (2004);18:60-8
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia (2010);53:2079-85
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2009);32:193-203
   PubMed Web of Science ®Google Scholar
• Petrie JR, Adler A, Vella S. What to add in with metformin in type 2 diabetes? QJM (2011);104:185-92
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002);287:360-72
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care (2007);30:1335-43
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2007);9:194-205
   PubMed Web of Science ®Google Scholar
• Seck T, Nauck MA, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract (2010);64:562-76
   PubMed Web of Science ®Google Scholar
• Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2011);13:160-8
   PubMed Web of Science ®Google Scholar
• Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther (2007);29:1607-19
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care (2005);28:1245-9
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord (2010);10:7
   PubMed Web of Science ®Google Scholar
• Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care (2005);28:2948-61
   PubMed Web of Science ®Google Scholar
• Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care (1997);20:135-41
   PubMed Web of Science ®Google Scholar
• Davis SN, Shavers C, Costa F. Differential gender responses to hypoglycemia are due to alterations in CNS drive and not glycemic thresholds. Am J Physiol Endocrinol Metab (2000);279:E1054-63
   Google Scholar
• Diamond MP, Jones T, Caprio S, et al. Gender influences counterregulatory hormone responses to hypoglycemia. Metabolism (1993);42:1568-72
   PubMed Web of Science ®Google Scholar
• Amiel SA, Maran A, Powrie JK, et al. Gender differences in counterregulation to hypoglycaemia. Diabetologia (1993);36:460-4
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ (2010);340:b5444
   PubMed Web of Science ®Google Scholar
• Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation (2011);123:342-8
   PubMed Web of Science ®Google Scholar
• Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev (2008);24:353-63
   PubMed Web of Science ®Google Scholar
• Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970);19:789-815
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol (2009);46:145-54
   PubMed Web of Science ®Google Scholar
• Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia (2006);49:930-6
   PubMed Web of Science ®Google Scholar
• Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care (2002);25:2244-8
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011);32:1900-8
   PubMed Web of Science ®Google Scholar
• Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med (2005);22:497-502
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (2009);339:b4731
   PubMed Web of Science ®Google Scholar
• Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia (2010);53:2546-53
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Engel SS, Golm GT, et al. Cardiovascular safety of sitagliptin versus a sulphonylurea in patients with type 2 diabetes mellitus: a pooled analysis (abstract). Presented at the (2011) International Diabetes Federation meeting, Dubai, UAE
   Google Scholar